Connect Biopharma Announces Promising Phase 2 Data for Rademikibart in Asthma and COPD, with Topline Results Expected in 1H 2026
Reuters
Sep 29
<a href="https://laohu8.com/S/CNTB">Connect Biopharma</a> Announces Promising Phase 2 Data for Rademikibart in Asthma and COPD, with Topline Results Expected in 1H 2026
Connect Biopharma Holdings Limited has announced new data supporting its investigational anti-interleukin-4-receptor alpha (IL-4Rα) antibody, rademikibart, at the European Respiratory Society (ERS) Congress 2025. The data demonstrated rapid and significant improvements in lung function and asthma control among patients, with the greatest benefits observed in those with elevated baseline levels of type 2 inflammatory markers. The results also showed a significant reduction in annualized exacerbations in patients with one or more elevated type 2 inflammatory markers at baseline. These findings support the ongoing Phase 2 Seabreeze STAT studies evaluating rademikibart for acute exacerbations in asthma and COPD. Connect Biopharma expects to report topline data from these studies in the first half of 2026. The company has made the presentations available on its website under the publications and presentations section.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9536355-en) on September 29, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.